COM:NRXPHARMA
NRx Pharmaceuticals
- Stock
Last Close
1.23
22/11 21:00
Market Cap
25.25M
Beta: -
Volume Today
79.66K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | 107K - | 107K 0% | -3.50K 103.27% | -3.50K 0% | ||||
average payables | 318.38K - | 586.77K 84.30% | 1.89M 221.71% | 3.42M 81.17% | 2.88M 15.75% | 3.35M 16.40% | ||
average receivables | 415.50K - | 415.50K 0% | 3.50K 99.16% | 3.50K 0% | ||||
book value per share | 26.57 - | 26.60 0.10% | 10.60 60.15% | -1.28 112.05% | 0.44 134.72% | 0.11 74.60% | -0.15 237.47% | |
capex per share | -0.00 - | -0.00 155.66% | -0.00 1.91% | |||||
capex to depreciation | -1 - | -3.50 250% | -2.50 28.57% | |||||
capex to operating cash flow | 0.00 - | 0.00 78.97% | 0.00 35.48% | |||||
capex to revenue | ||||||||
cash per share | 26.57 - | 27.07 1.87% | 11.50 57.52% | 0.23 98.01% | 0.59 157.62% | 0.30 48.17% | 0.06 80.11% | |
days of inventory on hand | 86.08 - | |||||||
days payables outstanding | 199.85 - | 1.27K - | 338.14K - | |||||
days sales outstanding | ||||||||
debt to assets | 0.01 - | 0.06 524.35% | 0.27 345.35% | 0.02 94.16% | 0.41 2,475.94% | 1.25 207.18% | ||
debt to equity | 0.01 - | 0.07 566.77% | -0.02 127.52% | 0.02 236.73% | 1.42 5,605.86% | -0.78 154.96% | ||
dividend yield | ||||||||
earnings yield | 0.00 - | 0.01 458.56% | -0.01 206.65% | -0.32 2,065.71% | -0.48 50.94% | -0.87 79.24% | ||
enterprise value | 24.86M - | 27.35M 10.01% | 31.45M 15.01% | 835.15M 2,555.33% | 197.18M 76.39% | 63.47M 67.81% | 39.42M 37.90% | |
enterprise value over ebitda | 331.83 - | 63.84 80.76% | -16.25 125.46% | -1.70 89.52% | -1.42 16.52% | -1.43 0.54% | ||
ev to operating cash flow | -183.04 - | -57.79 68.43% | -39.68 31.35% | -368.72 829.34% | -5.23 98.58% | -1.60 69.47% | -1.82 14.00% | |
ev to sales | ||||||||
free cash flow per share | -0.05 - | -0.18 248.42% | -0.28 57.39% | -0.07 76.78% | -0.80 1,115.05% | -0.60 24.77% | -0.29 52.72% | |
free cash flow yield | -0.01 - | -0.02 230.66% | -0.03 51.45% | -0.00 89.91% | -0.17 6,102.35% | -0.54 223.95% | -0.62 14.08% | |
graham net net | 26.54 - | 26.59 0.19% | 10.58 60.23% | -1.11 110.53% | 0.33 130.02% | 0.03 92.50% | -0.19 860.96% | |
graham number | 3.89 - | 5.92 52.10% | 3.22 45.61% | 3.91 21.37% | 1.17 70.16% | 1.18 1.05% | ||
income quality | -7.16 - | -1.94 72.89% | 0.04 102.25% | 0.41 826.12% | 1.00 146.84% | 0.72 28.17% | ||
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -917.63 - | -6.43K 601.06% | 9.69 100.15% | -229.89 2,472.08% | ||||
interest debt per share | 0.26 - | 0.70 165.74% | 0.02 96.45% | 0.01 54.10% | 0.09 691.12% | 0.12 35.54% | ||
inventory turnover | 4.24 - | |||||||
invested capital | 0.01 - | 0.07 566.77% | -0.02 127.52% | 0.02 236.73% | 1.42 5,605.86% | -0.78 154.96% | ||
market cap | 25.31M - | 26.67M 5.37% | 29.50M 10.62% | 836.21M 2,734.61% | 224.27M 73.18% | 73.00M 67.45% | 34.85M 52.26% | |
net current asset value | 443.20K - | -1.23M 376.90% | -2.50M 104.10% | -43.78M 1,647.98% | 20.79M 147.49% | 7.39M 64.47% | -12.16M 264.65% | |
net debt to ebitda | 8.24 - | 3.96 51.91% | 0.02 99.48% | 0.23 1,031.84% | 0.21 8.77% | -0.17 177.57% | ||
net income per share | 0.03 - | 0.15 480.47% | -0.36 345.49% | -1.53 324.27% | -0.54 64.95% | -0.40 25.72% | ||
operating cash flow per share | -0.05 - | -0.18 248.42% | -0.28 57.39% | -0.07 76.80% | -0.80 1,115.90% | -0.60 24.78% | -0.29 52.71% | |
payables turnover | 1.83 - | 0.29 - | 0.00 - | |||||
receivables turnover | ||||||||
research and ddevelopement to revenue | ||||||||
return on tangible assets | 0.00 - | 0.01 1,263.81% | -4.20 33,069.66% | -2.19 47.81% | -1.36 37.71% | -4.12 201.99% | ||
revenue per share | ||||||||
roe | 0.00 - | 0.01 1,356.48% | 0.28 1,937.46% | -3.45 1,321.93% | -4.76 37.97% | 2.57 154.03% | ||
roic | -0.01 - | -0.02 63.54% | 0.29 1,616.80% | -4.18 1,567.53% | -2.19 47.65% | 10.73 589.60% | ||
sales general and administrative to revenue | ||||||||
shareholders equity per share | 26.57 - | 26.60 0.10% | 10.60 60.15% | -1.28 112.05% | 0.44 134.72% | 0.11 74.60% | -0.15 237.47% | |
stock based compensation to revenue | ||||||||
tangible asset value | 69.47M - | 69.54M 0.10% | 29.50M 57.58% | -43.77M 248.37% | 20.81M 147.53% | 7.41M 64.39% | -11.73M 258.36% | |
tangible book value per share | 26.57 - | 26.60 0.10% | 10.60 60.15% | -1.28 112.05% | 0.44 134.72% | 0.11 74.60% | -0.15 237.47% | |
working capital | 443.20K - | -537.22K 221.21% | -552.95K 2.93% | -43.23M 7,718.76% | 20.79M 148.09% | 9.21M 55.70% | -12.16M 232.07% |
All numbers in (except ratios and percentages)